Sentence examples for rash dose from inspiring English sources

These findings, together with the reports of efficacy of lower doses of erlotinib in patients with known EGFR mutations suggest that, in the presence of rash, dose reductions to 'subtherapeutic' levels remain effective and may prevent unnecessary early treatment termination (Lind et al, 2009).

In patients with febrile neutropaenia, grade 4 neutropaenia, grade 3 4 thrombocytopaenia, serum creatinine >1.2 mg dl−1, or grade 3 4 diarrhoea, oral mucositis, or rash, doses of S-1 and cisplatin were reduced starting from the next cycle.

Only one participant developed rash after dose 2 in the MMR/MMRV group.

She was re-challenged with erlotinib (150 mg daily ) in October 2009, and experienced grade 3 skin rash without dose modification.

However, imaging excluded this and the liver function improved, together with the rash, after dose reduction of nitazoxanide.

Four patients (7%) developed a grade 3 skin rash requiring dose reduction of Erlotinib to 100 mg daily.

Among the 11 patients in the 135 mg QW cohort, one patient experienced two DLTs of grade 1 and grade 2 skin rash requiring dose modification.

There were no DLTs in the 45 mg QOD cohort, but among the 11 patients treated with 60 mg QOD one patient developed a DLT (grade 2 skin rash requiring dose modification).

Dose-limiting diarrhoea and rash precluded further dose escalation and possibly preclude the delivery of a dose required to adequately suppress the MAPK pathway.

The results of the study revealed that the dose-limiting toxicity was a skin rash, and a dose of 0.45-0.6 mg/kg was recommended for further phase II evaluation.

Prophylactic treatment for rash and ribavirin dose reductions in 68% may have minimized dermatologic side effects.